Boston Scientific is in a demographic sweet spot. An ageing population and increasing longevity is helping it build a global proposition in medical devices, focused on many of the illnesses associated with longer life. Its expertise in non-invasive medicine provides an alternative to surgery and a less expensive, gentler treatment option in areas including cardiology, urology and neurology.
A key element of the Massachusetts-based company’s expansion over recent years has been acquisitions, in which the company has taken stakes in small, innovative companies and looked to help them scale. Boston has made about 12 acquisitions over the past 18 months, including in August 2019 the $4.2bn purchase of UK-based device and drug maker BTG.
